Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
oral formulation
Biotech
Viking to charge quickly into phase 3 with obesity med
Viking will launch a longship into phase 3 for the obesity drug VK2735 sooner than expected, with a clinical program expected to top $300 million.
Annalee Armstrong
Jul 25, 2024 9:19am
Structure patches up shares after GLP-1 linked to 6% weight loss
Jun 3, 2024 10:17am
Pfizer drops oral obesity drug after seeing liver safety concern
Jun 26, 2023 9:11am
Lilly links oral drug to 15% weight loss, setting bar for Pfizer
Jun 26, 2023 8:35am
Merck's chronic cough med gets a nay from FDA
Jan 24, 2022 10:50am
Sensorion sinks as lead hearing loss med fails phase 2
Jan 19, 2022 10:03am
